Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ALPS GroupALPS +4.66%10 EV-to-EBIT is -32.32 as of Jul. 17, 2026. GuruFocus rates ALPS with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 372 Biotechnology companies, ALPS Group ranks worse than 268816.94% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ALPS Group's Enterprise Value for the quarter that ended in Sep. 2025 was $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ALPS Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was $-2.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPS Group EV-to-EBIT Related Terms
ALPS Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for ALPS Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPS Group EV-to-EBIT Chart
ALPS Group Annual Data
Trend
Mar23
Mar24
Mar25
EV-to-EBIT
0.00
0.00
0.00
ALPS Group Semi-Annual Data
Mar23
Mar24
Sep24
Mar25
Sep25
EV-to-EBIT
0.00
0.00
0.00
0.00
0.00
ALPS vs CUE, AARD, KLRS: EV-to-EBIT Comparison
For the Biotechnology subindustry, ALPS Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALPS Group EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALPS Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ALPS Group's EV-to-EBIT falls into.
ALPS Group's current Enterprise Value is $80.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ALPS Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was $-2.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPS Group (ALPS) has a EV-to-EBIT of -32.32 as of Jul. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ALPS Group and its competitors. According to the industry distribution chart, ALPS Group ranks #999999 out of 372 companies in the Biotechnology industry.
Is ALPS Group's EV-to-EBIT too high?
ALPS Group's current EV-to-EBIT is -32.32. Based on the distribution chart, ALPS Group ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ALPS Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does ALPS Group's EV-to-EBIT compare to CUE and AARD?
According to the Biotechnology industry distribution chart, ALPS Group ranks #999999 out of 372 companies for EV-to-EBIT. This places ALPS Group in the lower half of its industry. The industry median EV-to-EBIT is 13.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ALPS Group and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ALPS Group's current EV-to-EBIT is -32.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALPS Group stock overvalued right now?
ALPS Group (ALPS) has a current EV-to-EBIT of -32.32. The current EV-to-EBIT is -32.32. ALPS Group's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ALPS Group (ALPS), the current EV-to-EBIT is -32.32 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
10GF Score
Get the complete analysis for ALPS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPS has been successfully added to your 
